Q-omics provides the consensus-scored ZNF731P profile across patient tissues and cancer cell-line models. ZNF731P expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZNF731P is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, ZNF731P RNA expression shows 20,373 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KIRC, and UVM as cancer lineages where ZNF731P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF731P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF731P survival associations across molecular data types. ZNF731P RNA expression shows survival associations in the most cancer types (27). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF731P RNA expression–survival associations across cancer types. High ZNF731P expression shows unfavorable associations in ACC, LGG, CESC and KIRC, but favorable associations in BLCA and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ZNF731P RNA expression.
This table summarizes ZNF731P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF731P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF731P shows higher tumor expression in KIRC, BLCA, HNSC, LIHC, KIRP and STAD. The KIRC box plot shows higher ZNF731P RNA expression in tumor versus normal tissue (log2 FC = +0.648, t-test p < 0.001).
This table shows molecular features associated with ZNF731P in patient tissues and cancer cell lines. In patient samples, ZNF731P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
